Myocardial ischemia occurs when blood flow to heart muscle or myocardium is obstructed by a complete or partial blockage of a coronary artery by a buildup of plaques (atherosclerosis). It is also called cardiac ischemia. The most common symptom is chest pressure or pain, usually on the left side of the body (angina pectoris). Some other sign & symptoms are neck or jaw pain, fast heartbeat, shortness of breath, shoulder or arm pain, sweating, nausea & vomiting and fatigue.
Some of the risk factors include high blood pressure, obesity, diabetes, tobacco, high blood triglyceride level, high blood cholesterol level, waist circumference, waist circumference and lack of physical activity. Apart from this, few of the complications include irregular heart rhythm, heart failure and heart attack.
According to study, “Global Myocardial Ischemia Market Research Report Information: Type (Symptomatic, Asymptomatic) Treatment & Diagnosis (ECG, Antiplatelet Agents) End-user (Hospitals & Clinics, Diagnostic Centers, Ambulatory Surgical Centers) – Forecast Till 2023” the key companies operating in the global myocardial ischemia market are Taxus Cardium, Edwards Lifesciences Corporation, ViroMed Co. Ltd, Daiichi Sankyo Company Limited, Merck KGaA, Novartis AG, Boston Scientific Corporation, Boehringer Ingelheim International GmbH, Bayer AG, AstraZeneca, Johnson & Johnson Services Inc. (Janssen Global Services LLC), Atrium Medical Corporation, Pfizer Inc., Vasade Biosciences, Inc., Baxter International, Inc. Various pharmaceutical companies are frequently trying to come up with novel therapeutic developments for the treatment of myocardial ischemia.
Based on type, myocardial ischemia market is segmented into symptomatic and asymptomatic. Based on condition type, market is segmented into blood clot, coronary artery disease and coronary artery spasm. Based on treatment & diagnosis, market is segmented into diagnosis and treatment. Diagnosis segment is further sub-segmented into stress and imaging tests. Imaging tests include Electrocardiogram (ECG), coronary angiography, nuclear scan, holter monitoring and cardiac CT scan. Treatment segment is further sub-segmented into surgery (angioplasty & stenting, enhanced external counter pulsation and coronary artery bypass surgery) and medications (antiplatelet agents (vorapaxar, aspirin, and clopidogre), antithrombotic agents, beta-adrenergic blockers, glycoprotein IIb/IIIa inhibitors, angiotensin-receptor blockers, thrombolytics (tenecteplase and alteplase [t-PA]), angiotensin-converting enzyme (ACE) inhibitors, and analgesics (morphine sulfate)). In addition, based on end-user, market is segmented into diagnostic centers, hospitals & clinics, ambulatory surgery centers, and others.
The myocardial ischemia market is driven by high prevalence of coronary heart disease, followed by change in lifestyle and rise in incidence of diabetes. However, side effects related to medications and high cost of therapeutic surgeries may impact the market. Moreover, increase in acceptance of newer treatment technologies is a key opportunity for market.
Based on geography, the North-American region holds major share, followed by European region in myocardial ischemia market owing to rise in awareness of the population about cardiovascular diseases, increase in competition from small market players and growth in technological advancements in the region. Asian-Pacific region is expected to witness higher growth rate due to increase in the prevalence of various heart-related diseases and continuously development in economies over the forecast period. It is anticipated that future of the market will be bright on account of presence of a well-developed healthcare sector and huge patient population during the forecast period.
To know more, click on the link below:-
Ankur Gupta, Head Marketing & Communications